Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential

We recently published 10 Stocks With Eye-Popping Gains; 7 Soar to Fresh Highs. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is one of the top performers on Monday.

Dianthus Therapeutics soared to a new record high on Monday, as investors cheered impressive results from its clinical trial of a potential treatment for generalized Myasthenia Gravis (gMG), a rare autoimmune disease causing muscle weakness.

At intra-day trading, Dianthus Therapeutics, Inc. (NASDAQ:DNTH) hit a new record high of $32.8 before trimming gains to finish the day just up by 20 percent at $31.80 apiece, after the company said that it saw significant and clinically meaningful improvements in the second phase of clinical trial for Claseprubart immediately in the first week, lasting through the 13th week.

“Claseprubart was generally well tolerated with no drug-related Serious Adverse Events (SAEs) or discontinuations due to any related adverse event. Claseprubart had a favorable clinical safety profile comparable to placebo with no treatment-related serious bacterial infections and no clinical symptoms of emergent autoimmune disorders observed,” Dianthus Therapeutics, Inc. (NASDAQ:DNTH) said. The trial enrolled 65 adult patients with gMG.

“Claseprubart has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need,” it added.

In other news, Dianthus Therapeutics, Inc. (NASDAQ:DNTH) announced that it has commenced an underwritten public offering to raise $150 million in fresh funds to advance preclinical and clinical development activities, as well as for working capital and general corporate purposes.

While we acknowledge the potential of DNTH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.